Venker Eric 4
4 · Roivant Sciences Ltd. · Filed Dec 11, 2025
Insider Transaction Report
Form 4
Venker Eric
President & Immunovant CEO
Transactions
- Exercise/Conversion
Common Shares
2025-12-09$3.85/sh+200,000$770,000→ 1,697,908 total - Sale
Common Shares
2025-12-09$20.85/sh−200,000$4,170,000→ 1,497,908 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-12-09−200,000→ 5,876,523 totalExercise: $3.85Exp: 2032-04-19→ Common Stock (200,000 underlying)
Footnotes (2)
- [F1]The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.
- [F2]Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).